Lower Intrinsic ADP-stimulated Mitochondrial Respiration Underlies in Vivo Mitochondrial Dysfunction in Muscle of Male Type 2 Diabetic Patients
Overview
Authors
Affiliations
Objective: A lower in vivo mitochondrial function has been reported in both type 2 diabetic patients and first-degree relatives of type 2 diabetic patients. The nature of this reduction is unknown. Here, we tested the hypothesis that a lower intrinsic mitochondrial respiratory capacity may underlie lower in vivo mitochondrial function observed in diabetic patients.
Research Design And Methods: Ten overweight diabetic patients, 12 first-degree relatives, and 16 control subjects, all men, matched for age and BMI, participated in this study. Insulin sensitivity was measured with a hyperinsulinemic-euglycemic clamp. Ex vivo intrinsic mitochondrial respiratory capacity was determined in permeabilized skinned muscle fibers using high-resolution respirometry and normalized for mitochondrial content. In vivo mitochondrial function was determined by measuring phosphocreatine recovery half-time after exercise using (31)P-magnetic resonance spectroscopy.
Results: Insulin-stimulated glucose disposal was lower in diabetic patients compared with control subjects (11.2 +/- 2.8 vs. 28.9 +/- 3.7 micromol x kg(-1) fat-free mass x min(-1), respectively; P = 0.003), with intermediate values for first-degree relatives (22.1 +/- 3.4 micromol x kg(-1) fat-free mass x min(-1)). In vivo mitochondrial function was 25% lower in diabetic patients (P = 0.034) and 23% lower in first-degree relatives, but the latter did not reach statistical significance (P = 0.08). Interestingly, ADP-stimulated basal respiration was 35% lower in diabetic patients (P = 0.031), and fluoro-carbonyl cyanide phenylhydrazone-driven maximal mitochondrial respiratory capacity was 31% lower in diabetic patients (P = 0.05) compared with control subjects with intermediate values for first-degree relatives.
Conclusions: A reduced basal ADP-stimulated and maximal mitochondrial respiratory capacity underlies the reduction in in vivo mitochondrial function, independent of mitochondrial content. A reduced capacity at both the level of the electron transport chain and phosphorylation system underlies this impaired mitochondrial capacity.
Chen J, Kastroll J, Bello F, Pangburn M, Murali A, Smith P Sci Rep. 2025; 15(1):8101.
PMID: 40057594 PMC: 11890589. DOI: 10.1038/s41598-025-92572-x.
Sinclair A, Abdelhafiz A Metabolites. 2025; 15(1).
PMID: 39852391 PMC: 11767933. DOI: 10.3390/metabo15010049.
Wang Z, Zhu H, Xiong W Front Med. 2025; .
PMID: 39821730 DOI: 10.1007/s11684-024-1116-0.
Vidyadharan V, Betancourt A, Smith C, Blesson C, Yallampalli C Int J Mol Sci. 2024; 25(23).
PMID: 39684571 PMC: 11641076. DOI: 10.3390/ijms252312860.
Mapping the mitochondrial landscape in T2DM: key findings from 2003-2023.
Tan Y, Liu M, Zhou X, Gao T, Fang J, Wang S Front Endocrinol (Lausanne). 2024; 15:1474232.
PMID: 39634184 PMC: 11614640. DOI: 10.3389/fendo.2024.1474232.